Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1245/s10434-025-18060-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prescription and self-reported use of endocrine therapy among black hormone receptor-positive breast cancer survivors in the Detroit Research on Cancer Survivors cohort.
Breast Cancer Res Treat
September 2025
Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA.
Purpose: Black women with hormone receptor-positive (HR +) breast cancer are twice as likely as White women to have weakly HR + tumors (1-10% positive cells). Patients with weakly HR + tumors are less frequently prescribed ET and have 60% higher mortality than strongly HR + tumors (> 10% positive cells). We evaluated factors associated with ET prescription and self-reported use among Black women with HR + breast cancer.
View Article and Find Full Text PDFDisease-Specific Mortality in Patients With Acromegaly Treated With Pegvisomant: An ACROSTUDY Analysis.
Endocr Connect
September 2025
Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Objective: Characterize disease-specific mortality rates in patients with acromegaly on pegvisomant and identify pertinent risk factors, including on-therapy insulin-like growth factor I (IGF-I) levels.
Design: Retrospective cohort analysis of ACROSTUDY, a global surveillance study of patients with acromegaly receiving pegvisomant.
Methods: Cumulative incidence function to estimate disease-specific mortality and regression analyses to characterize risk factors.
Expert consensus for prevention, diagnosis and management of persistent chemotherapy-induced alopecia.
J Eur Acad Dermatol Venereol
September 2025
Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Background: Persistent chemotherapy-induced alopecia (pCIA) is a distressing side effect of antineoplastic agents, imposing significant psychological burdens on cancer survivors. Despite its impact, there are no standardized guidelines for diagnosis, prevention or management.
Objective: To establish consensus-based definitions, diagnostic criteria, grading systems and management recommendations for pCIA.
A Novel Approach for Cisplatin-Resistant Esophageal Squamous Cell Carcinoma via Amino Acid Transporter LAT1 Inhibition.
Cancer Med
September 2025
Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
Background: Esophageal squamous cell carcinoma (ESCC) represents an aggressive cancer type associated with poor prognosis, often treated with neoadjuvant chemotherapy (NAC) using cisplatin-based regimens. However, cisplatin resistance limits therapeutic efficacy, necessitating a deeper understanding of resistance mechanisms. L-type amino acid transporter 1 (LAT1) plays a crucial role in amino acid uptake and is linked to cancer cell survival through activation of the mammalian target of rapamycin (mTOR) pathway.
View Article and Find Full Text PDFPregnancy and breast cancer in young women: current updates and future directions.
Ther Adv Med Oncol
September 2025
Division of Surgical Oncology, Department of Surgery, University of California, Los Angeles, 15503 Ventura Blvd, Suite 150, Los Angeles, CA 90095, USA.
The relationship between pregnancy and breast cancer is complicated. On one hand, pregnancy can influence breast cancer risk and tumor biology, and on the other, a breast cancer diagnosis and its subsequent management can significantly affect fertility, family planning, and future pregnancies. This interaction presents challenges unique to young women with breast cancer (YWBC).
View Article and Find Full Text PDF